ACCase dataset

If you use eFindSite, please cite the following papers:
1
2
If you use eThread, please cite the following papers:
1
2
If you use eRankPPI, please cite the following papers:
1
2
If you use eAromatic, please cite the following paper:
1
If you use CMS, please cite the following paper:
1
If you use GeauxDockd, please cite the following papers:
1
2
If you use eSynth, please cite the following paper:
1
If you use eBoxSize, please cite the following paper:
1
If you use the ACCase dataset, please cite the following paper:
1
If you use eModel-BDB, please cite the following paper:
1
If you use eToxPred, please cite the following paper:
1
If you use eFindSitePPI, please cite the following papers:
1
2
If you use TOUGH-D1, please cite the following paper:
1
If you use TOUGH-D1, please cite the following paper:
1
If you use TOUGH-M1, please cite the following paper:
1
If you use eMatchSite, please cite the following papers:
1
2
If you use eMolFrag, please cite the following paper:
1
If you use eVolver, please cite the following papers:
1
2
If you use eRepo-ORP, please cite the following papers:
1
2
If you use eToxPred, please cite the following paper:
1
 

Modeling data for the redesign of previously identified lead inhibitors of bacterial biotin carboxylase (BC) to expand the spectrum of organisms sensitive to amino-oxazole derivatives.

CMS

If you use eFindSite, please cite the following papers:
1
2
If you use eThread, please cite the following papers:
1
2
If you use eRankPPI, please cite the following papers:
1
2
If you use eAromatic, please cite the following paper:
1
If you use CMS, please cite the following paper:
1
If you use GeauxDockd, please cite the following papers:
1
2
If you use eSynth, please cite the following paper:
1
If you use eBoxSize, please cite the following paper:
1
If you use the ACCase dataset, please cite the following paper:
1
If you use eModel-BDB, please cite the following paper:
1
If you use eToxPred, please cite the following paper:
1
If you use eFindSitePPI, please cite the following papers:
1
2
If you use TOUGH-D1, please cite the following paper:
1
If you use TOUGH-D1, please cite the following paper:
1
If you use TOUGH-M1, please cite the following paper:
1
If you use eMatchSite, please cite the following papers:
1
2
If you use eMolFrag, please cite the following paper:
1
If you use eVolver, please cite the following papers:
1
2
If you use eRepo-ORP, please cite the following papers:
1
2
If you use eToxPred, please cite the following paper:
1
 

A new metric to assess the conformational similarity based on intermolecular protein-ligand contacts. In contrast to RMSD, the Contact Mode Score, or CMS, is less dependent on the ligand size and has the ability to handle flexible receptors. Further, the eXtended Contact Mode Score, or XCMS, was developed to compare binding poses of non-identical ligands bound to different proteins.

GeauxDock

If you use eFindSite, please cite the following papers:
1
2
If you use eThread, please cite the following papers:
1
2
If you use eRankPPI, please cite the following papers:
1
2
If you use eAromatic, please cite the following paper:
1
If you use CMS, please cite the following paper:
1
If you use GeauxDockd, please cite the following papers:
1
2
If you use eSynth, please cite the following paper:
1
If you use eBoxSize, please cite the following paper:
1
If you use the ACCase dataset, please cite the following paper:
1
If you use eModel-BDB, please cite the following paper:
1
If you use eToxPred, please cite the following paper:
1
If you use eFindSitePPI, please cite the following papers:
1
2
If you use TOUGH-D1, please cite the following paper:
1
If you use TOUGH-D1, please cite the following paper:
1
If you use TOUGH-M1, please cite the following paper:
1
If you use eMatchSite, please cite the following papers:
1
2
If you use eMolFrag, please cite the following paper:
1
If you use eVolver, please cite the following papers:
1
2
If you use eRepo-ORP, please cite the following papers:
1
2
If you use eToxPred, please cite the following paper:
1
 

An ultra-fast automated docking program, designed to predict how small ligands bind to pharmacologically relevant macromolecules. GeauxDock employs a novel hybrid force field, a mixed-resolution representation of protein-ligand complexes, and a Monte Carlo protocol for the efficient sampling of conformational space.

 

eAromatic

If you use eFindSite, please cite the following papers:
1
2
If you use eThread, please cite the following papers:
1
2
If you use eRankPPI, please cite the following papers:
1
2
If you use eAromatic, please cite the following paper:
1
If you use CMS, please cite the following paper:
1
If you use GeauxDockd, please cite the following papers:
1
2
If you use eSynth, please cite the following paper:
1
If you use eBoxSize, please cite the following paper:
1
If you use the ACCase dataset, please cite the following paper:
1
If you use eModel-BDB, please cite the following paper:
1
If you use eToxPred, please cite the following paper:
1
If you use eFindSitePPI, please cite the following papers:
1
2
If you use TOUGH-D1, please cite the following paper:
1
If you use TOUGH-D1, please cite the following paper:
1
If you use TOUGH-M1, please cite the following paper:
1
If you use eMatchSite, please cite the following papers:
1
2
If you use eMolFrag, please cite the following paper:
1
If you use eVolver, please cite the following papers:
1
2
If you use eRepo-ORP, please cite the following papers:
1
2
If you use eToxPred, please cite the following paper:
1
 

A program to calculate two geometric parameters for aromatic contacts between ligands and proteins. The first parameter is the Cartesian distance between the geometric centers of two rings, referred to as the distance. The second parameter is an angle between normal vectors of two aromatic rings, referred to as the angle.

 

Structural Bioinformatics

For more information see:
1
2
3
4
For more information see:
1
2
3
4
5
For more information see:
1
2
3
For more information see:
1
2
For more information see:
1
For more information see:
1
2
3
For more information see:
1
2
For more information see:
1
For more information see:
1
2
For more information see:
1
For more information see:
1
For more information see:
1
2
For more information see:
1
2
3
4
5
6
For more information see:
1
2
3
For more information see:
1
For more information see:
1
For more information see:
1
For more information see:
1
2
3
For more information see:
1
2

Network Pharmacology

For more information see:
1
2
3
4
For more information see:
1
2
3
4
5
For more information see:
1
2
3
For more information see:
1
2
For more information see:
1
For more information see:
1
2
3
For more information see:
1
2
For more information see:
1
For more information see:
1
2
For more information see:
1
For more information see:
1
For more information see:
1
2
For more information see:
1
2
3
4
5
6
For more information see:
1
2
3
For more information see:
1
For more information see:
1
For more information see:
1
For more information see:
1
2
3
For more information see:
1
2

Network Biology

For more information see:
1
2
3
4
For more information see:
1
2
3
4
5
For more information see:
1
2
3
For more information see:
1
2
For more information see:
1
For more information see:
1
2
3
For more information see:
1
2
For more information see:
1
For more information see:
1
2
For more information see:
1
For more information see:
1
For more information see:
1
2
For more information see:
1
2
3
4
5
6
For more information see:
1
2
3
For more information see:
1
For more information see:
1
For more information see:
1
For more information see:
1
2
3
For more information see:
1
2

Pharmacogenomics

For more information see:
1
2
3
4
For more information see:
1
2
3
4
5
For more information see:
1
2
3
For more information see:
1
2
For more information see:
1
For more information see:
1
2
3
For more information see:
1
2
For more information see:
1
For more information see:
1
2
For more information see:
1
For more information see:
1
For more information see:
1
2
For more information see:
1
2
3
4
5
6
For more information see:
1
2
3
For more information see:
1
For more information see:
1
For more information see:
1
For more information see:
1
2
3
For more information see:
1
2

Cheminformatics

For more information see:
1
2
3
4
For more information see:
1
2
3
4
5
For more information see:
1
2
3
For more information see:
1
2
For more information see:
1
For more information see:
1
2
3
For more information see:
1
2
For more information see:
1
For more information see:
1
2
For more information see:
1
For more information see:
1
For more information see:
1
2
For more information see:
1
2
3
4
5
6
For more information see:
1
2
3
For more information see:
1
For more information see:
1
For more information see:
1
For more information see:
1
2
3
For more information see:
1
2

Functional Genomics

For more information see:
1
2
3
4
For more information see:
1
2
3
4
5
For more information see:
1
2
3
For more information see:
1
2
For more information see:
1
For more information see:
1
2
3
For more information see:
1
2
For more information see:
1
For more information see:
1
2
For more information see:
1
For more information see:
1
For more information see:
1
2
For more information see:
1
2
3
4
5
6
For more information see:
1
2
3
For more information see:
1
For more information see:
1
For more information see:
1
For more information see:
1
2
3
For more information see:
1
2